Saheli Sadanand
@SaheliSadanand
Deputy Editor @NatureMedicine | Handling research in #oncology #immunology #immunotherapy | Mom | Fan of vaccines & 🦖 | Views all mine
ID:1102268065201487873
03-03-2019 18:02:40
1,4K Tweets
1,8K Followers
573 Following
Advances in bioengineering and organic chemistry have enabled targeting of the previously ‘undruggable’ #KRAS ; our latest review from Eileen M O’Reilly & colleagues discusses the successes, challenges & future of KRAS therapeutics in #cancer
Memorial Sloan Kettering Cancer Center
nature.com/articles/s4159…
#OpenAccess in Nature Medicine
Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learning
nature.com/articles/s4159…
Fantastic study that uses tens of thousands of cytology cases for training & test sets for assessing CUP patients.
📢 Looking for your next conference after #AACR24 ? Check out our upcoming Nature Conferences on #cancer #immunotherapy ! Planned w/ Nature Rev Immunol Nature Cancer Nature Immunology
🗓️ Abstract & Early Registration Deadline = THIS Fri, April 12th
🎟️More details here: go.nature.com/CancerImm
In children with refractory cancer, ex vivo testing of tumor cells for drug sensitivity and genomic profiling guided successful therapy ('functional precision medicine') for some
nature.com/articles/s4159…
Nature Medicine
New data show that ex vivo drug screening of pediatric #cancer samples can identify effective therapies. If validated, this could herald a new approach to #precisiononcology
News & Views from Emmy Dolman, Paul Ekert Peter Mac Cancer Centre Childrens Cancer Institute
nature.com/articles/s4159…
At the #CancerVaccines #AACR24 session? Check out this recent trial led by Dr. Shubham Pant Eileen M O’Reilly Elicio Therapeutics reporting results of a lymph node-targeting mutant #KRAS peptide vaccine given to patients with #PancreaticCancer and #ColorectalCancer nature.com/articles/s4159…
Attending the clinical trials #AACR24 plenary session on novel #immunotherapy strategies? Check out this phase 1/2 trial of an #OncolyticVirus + anti-PD-1 in patients with recurrent #glioblastoma . Work led by Farshad Nassiri gelareh-zadeh nature.com/articles/s4159…
NEW online & being presented this afternoon at the #AACR24 poster session: A personalised DNA #CancerVaccine + anti-PD1 was safe & led to encouraging clinical efficacy in patients with advanced #LiverCancer Mark Yarchoan Johns Hopkins Kimmel Cancer Center Niranjan Sardesai #HCC nature.com/articles/s4159…
Outstanding talk by Jakob Nikolas Kather at the #AACR24 Opening Plenary Session, providing an overview of #AI advances in #digitalpathology reaching clinical oncology.
Also very proud to see Nature Medicine pioneering impactful studies in this field and staying at the forefront of innovation
Check out this study from #AACR24 opening plenary speaker Jakob Nikolas Kather: a decentralized, privacy-preserving ML framework used to train an #AI system identifies actionable molecular changes in patients with #ColorectalCancer with routine #histopathology data nature.com/articles/s4159…
At the #AACR24 #CellTherapies in solid tumors session? Check out our 2 recent trials on #CARTcells in patients with #glioblastoma !
Work led by Christine Brown City of Hope: nature.com/articles/s4159…
Work led by Stephen Bagley DrORourke Penn Medicine: nature.com/articles/s4159…
Easter paper of the month with Matt Galsky - gem/cis/nivo with bladder sparing approaches and single agent nivo in responders. Magic data. Move to a cystectomy free era I hope . Nature Medicine podcasters.spotify.com/pod/show/the-u…
Immune checkpoint blockade plus a vaccine including self-amplifying mRNA-encoded neoantigens derived from common oncogenic driver mutations was safe and elicited neoantigen-specific T cell responses in patients with advanced solid tumors #CancerVaccine
nature.com/articles/s4159…